De-escalating treatment indications for patients who achieve metabolic goals
Journal
Diabetes Research and Clinical Practice
ISSN
0168-8227
Publisher
Elsevier
Date Issued
2024
Author(s)
García-Ulloa, Ana Cristina
Jaime-Casas, Salvador
Rosado-Lozoya, Johanna S.
Serrano-Pérez, Nancy H.
Hernández-Juárez, Diana
Cárdenas-Fragoso, José Luis
Briones-García, Luis Eduardo
Jiménez-Soto, Rodolfo
García-Padilla, Carlos
García-Lara, Juan
Aguilar-Salinas, Carlos A.
Hernández-Jiménez, Sergio
Type
Resource Types::text::journal::journal article
Abstract
Introduction: Robust evidence exists regarding initiation, intensification or modification of treatments. Recommendations to de-escalate therapy are lacking, specifically in diabetes. A successful treatment de-intensification reduces overtreatment, polypharmacy, and risk of adverse effects. Objective: To encompass current recommendations for deprescribing common drugs and create a consensus among health professionals. Methods: We reviewed four databases for deprescribing approaches published between 2010 and 2022. Articles were divided into different groups of drugs (for uric-acid, hypoglycemic, lipid-lowering, and psychotropic drugs).©Elsevier
How to cite
Cristina García-Ulloa, A., Jaime-Casas, S., Rosado-Lozoya, J., Serrano-Pérez, N. H., Hernández-Juárez, D., Luis Cárdenas-Fragoso, J., Eduardo Briones-García, L., Jiménez-Soto, R., García-Padilla, C., García-Lara, J., Aguilar-Salinas, C. A., & Hernández-Jiménez, S. (2024). De-escalating treatment indications for patients who achieve metabolic goals. In Diabetes Research and Clinical Practice (Vol. 208, p. 111096). Elsevier BV. https://doi.org/10.1016/j.diabres.2024.111096